First Eagle Investment Management LLC Raises Stock Position in Elevance Health, Inc. $ELV

First Eagle Investment Management LLC grew its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 0.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,022,874 shares of the company’s stock after purchasing an additional 24,271 shares during the period. Elevance Health comprises approximately 2.5% of First Eagle Investment Management LLC’s holdings, making the stock its 10th largest holding. First Eagle Investment Management LLC’s holdings in Elevance Health were worth $1,410,219,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ELV. Sei Investments Co. lifted its position in Elevance Health by 7.7% during the 2nd quarter. Sei Investments Co. now owns 163,668 shares of the company’s stock worth $63,666,000 after buying an additional 11,745 shares in the last quarter. Glenview Trust co lifted its position in Elevance Health by 41.5% during the 2nd quarter. Glenview Trust co now owns 1,619 shares of the company’s stock worth $630,000 after buying an additional 475 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in Elevance Health by 6.9% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 65,945 shares of the company’s stock worth $25,650,000 after buying an additional 4,272 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Elevance Health by 5.0% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,371 shares of the company’s stock worth $16,478,000 after buying an additional 2,012 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its position in Elevance Health by 111.8% during the 2nd quarter. Quantinno Capital Management LP now owns 43,911 shares of the company’s stock worth $17,080,000 after buying an additional 23,180 shares in the last quarter. 89.24% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ELV shares. Sanford C. Bernstein boosted their price target on shares of Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research report on Friday, April 24th. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Jefferies Financial Group lowered their price objective on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Evercore boosted their price objective on shares of Elevance Health from $345.00 to $360.00 in a research note on Thursday, April 23rd. Finally, Guggenheim boosted their price objective on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Thirteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $384.58.

Elevance Health Stock Up 0.9%

Elevance Health stock opened at $381.58 on Tuesday. The firm has a market capitalization of $82.86 billion, a PE ratio of 16.23, a P/E/G ratio of 2.15 and a beta of 0.66. The company’s 50-day moving average is $315.03 and its 200-day moving average is $332.51. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $424.24. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. During the same period in the previous year, the business earned $11.97 EPS. Elevance Health’s revenue for the quarter was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Sell-side analysts anticipate that Elevance Health, Inc. will post 26.79 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a $1.72 dividend. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health’s dividend payout ratio is 29.26%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.